BMS launches dual immunotherapy for metastatic melanoma

Bristol-Myers Squibb (BMS) has launched a dual immunotherapy treatment for metastatic melanoma, a type of advanced skin cancer. The therapy combines two immune checkpoint inhibitors to enhance anti-tumor responses.